Palonosetron View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-05

AUTHORS

M. Asif A. Siddiqui, Lesley J. Scott

ABSTRACT

Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters. More... »

PAGES

1125-1132

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006

DOI

http://dx.doi.org/10.2165/00003495-200464100-00006

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1037955349

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15139789


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiemetics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Palonosetron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinuclidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serotonin 5-HT3 Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Springer (New Zealand)", 
          "id": "https://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Siddiqui", 
        "givenName": "M. Asif A.", 
        "id": "sg:person.01303054417.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303054417.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Springer (New Zealand)", 
          "id": "https://www.grid.ac/institutes/grid.420067.7", 
          "name": [
            "Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Scott", 
        "givenName": "Lesley J.", 
        "id": "sg:person.01244653776.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244653776.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/cncr.11817", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010335838"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-198300251-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021192528", 
          "https://doi.org/10.2165/00003495-198300251-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdh047", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026990645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb13283.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031465223"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199652050-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037308623", 
          "https://doi.org/10.2165/00003495-199652050-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(98)00417-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038757244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(83)90418-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042962166"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043604506", 
          "https://doi.org/10.1038/bjc.1997.507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1997.507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043604506", 
          "https://doi.org/10.1038/bjc.1997.507"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdg417", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047729604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.1995.tb13282.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050303878"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074458360", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/ajhp/56.8.729", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074458360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.9.2971", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549933"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05", 
    "datePublishedReg": "2004-05-01", 
    "description": "Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003495-200464100-00006", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "64"
      }
    ], 
    "name": "Palonosetron", 
    "pagination": "1125-1132", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "b4ce7f73c113f8646b6074566abd584e878929ee062fc2678e423426c1d5c6a7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15139789"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-200464100-00006"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1037955349"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-200464100-00006", 
      "https://app.dimensions.ai/details/publication/pub.1037955349"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70027_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003495-200464100-00006"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200464100-00006'


 

This table displays all metadata directly associated to this object as RDF triples.

165 TRIPLES      21 PREDICATES      54 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-200464100-00006 schema:about N02f63dc7b2be4b2db2b4ab127248a30c
2 N0b4524aa7aa14b3fa540ad5fe320b998
3 N0ec2a446dfb44c71b8e868194a9e1e70
4 N256f0ceef07445a0af56fff456c670ce
5 N701c852c40944caa8154a3d93d3ac0c0
6 N90861a7b1b894faaa9cd8527c1e20ba5
7 Nacc0d84acbb34fa8b7fdb0c3af7858b2
8 Naf87f083531e42388fe886a57b8e4222
9 Nb77472fa0a0040c0b0cde544c0e07c70
10 Nba9463fe51f8470892430d5c6719a3c9
11 Ne78a3628757c40f381bb8bda496155c2
12 Nfec2861c81a94f2493ce920b7b3d532e
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N93cf180b72524352b96d244a6c16b02e
16 schema:citation sg:pub.10.1038/bjc.1997.507
17 sg:pub.10.2165/00003495-198300251-00002
18 sg:pub.10.2165/00003495-199652050-00002
19 https://app.dimensions.ai/details/publication/pub.1074458360
20 https://doi.org/10.1002/cncr.11817
21 https://doi.org/10.1016/0277-5379(83)90418-2
22 https://doi.org/10.1016/s0959-8049(98)00417-1
23 https://doi.org/10.1093/ajhp/56.8.729
24 https://doi.org/10.1093/annonc/mdg417
25 https://doi.org/10.1093/annonc/mdh047
26 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x
27 https://doi.org/10.1111/j.1476-5381.1995.tb13283.x
28 https://doi.org/10.1200/jco.1999.17.9.2971
29 schema:datePublished 2004-05
30 schema:datePublishedReg 2004-05-01
31 schema:description Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate (62%) plasma protein binding. In two randomised, double-blind trials in 1132 cancer patients receiving moderately emetogenic chemotherapy, intravenous palonosetron 0.25 mg was more effective than intravenous ondansetron 32 mg in producing a complete response (no emesis, no use of rescue medication) during acute (0-24 hours) or delayed (24-120 hours) phases, and similar to intravenous dolasetron 100 mg in acute, but more effective in delayed phase. Palonosetron 0.75 mg was similar to ondansetron (acute and delayed phase) or dolasetron (acute phase), but more effective than dolasetron in delayed phase. In patients receiving highly emetogenic chemotherapy (n = 667), the complete response rates during acute and delayed phases with intravenous palonosetron (0.25 or 0.75 mg) were similar to those seen in intravenous ondansetron 32 mg recipients in a randomised, double-blind trial. Intravenous palonosetron was generally well tolerated in clinical trials, with few adverse events being treatment related. Palonosetron had no significant effect on the corrected QT interval or laboratory parameters.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N5fdf10e8d9a64a57b65df7b849fd56a1
36 Na5566705a7254670b386466f3487758d
37 sg:journal.1084788
38 schema:name Palonosetron
39 schema:pagination 1125-1132
40 schema:productId N0d0245c996c14af6b46612346a16f2dc
41 N2c7c6fec8df0447a90298165d0f15f5e
42 N908121b3cd894c61a323381bd87f3e5e
43 N95b4c51ac7854733b96b35b38f1c7ef8
44 Ne8ccbdd56f4f47e09b6f6a279f6879ae
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037955349
46 https://doi.org/10.2165/00003495-200464100-00006
47 schema:sdDatePublished 2019-04-11T12:35
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher N9a7a1870910941f88432f3a7fe4ac1d9
50 schema:url http://link.springer.com/10.2165/00003495-200464100-00006
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N02f63dc7b2be4b2db2b4ab127248a30c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
55 schema:name Antiemetics
56 rdf:type schema:DefinedTerm
57 N0b4524aa7aa14b3fa540ad5fe320b998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Quinuclidines
59 rdf:type schema:DefinedTerm
60 N0d0245c996c14af6b46612346a16f2dc schema:name pubmed_id
61 schema:value 15139789
62 rdf:type schema:PropertyValue
63 N0ec2a446dfb44c71b8e868194a9e1e70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
64 schema:name Antineoplastic Agents
65 rdf:type schema:DefinedTerm
66 N256f0ceef07445a0af56fff456c670ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Injections, Intravenous
68 rdf:type schema:DefinedTerm
69 N2c7c6fec8df0447a90298165d0f15f5e schema:name dimensions_id
70 schema:value pub.1037955349
71 rdf:type schema:PropertyValue
72 N5fdf10e8d9a64a57b65df7b849fd56a1 schema:issueNumber 10
73 rdf:type schema:PublicationIssue
74 N701c852c40944caa8154a3d93d3ac0c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Palonosetron
76 rdf:type schema:DefinedTerm
77 N908121b3cd894c61a323381bd87f3e5e schema:name doi
78 schema:value 10.2165/00003495-200464100-00006
79 rdf:type schema:PropertyValue
80 N90861a7b1b894faaa9cd8527c1e20ba5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Nausea
82 rdf:type schema:DefinedTerm
83 N93cf180b72524352b96d244a6c16b02e rdf:first sg:person.01303054417.19
84 rdf:rest Nde5387c28e46499ab38fa67b86fd8a45
85 N95b4c51ac7854733b96b35b38f1c7ef8 schema:name nlm_unique_id
86 schema:value 7600076
87 rdf:type schema:PropertyValue
88 N9a7a1870910941f88432f3a7fe4ac1d9 schema:name Springer Nature - SN SciGraph project
89 rdf:type schema:Organization
90 Na5566705a7254670b386466f3487758d schema:volumeNumber 64
91 rdf:type schema:PublicationVolume
92 Nacc0d84acbb34fa8b7fdb0c3af7858b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Isoquinolines
94 rdf:type schema:DefinedTerm
95 Naf87f083531e42388fe886a57b8e4222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Neoplasms
97 rdf:type schema:DefinedTerm
98 Nb77472fa0a0040c0b0cde544c0e07c70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Vomiting
100 rdf:type schema:DefinedTerm
101 Nba9463fe51f8470892430d5c6719a3c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Humans
103 rdf:type schema:DefinedTerm
104 Nde5387c28e46499ab38fa67b86fd8a45 rdf:first sg:person.01244653776.31
105 rdf:rest rdf:nil
106 Ne78a3628757c40f381bb8bda496155c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Serotonin 5-HT3 Receptor Antagonists
108 rdf:type schema:DefinedTerm
109 Ne8ccbdd56f4f47e09b6f6a279f6879ae schema:name readcube_id
110 schema:value b4ce7f73c113f8646b6074566abd584e878929ee062fc2678e423426c1d5c6a7
111 rdf:type schema:PropertyValue
112 Nfec2861c81a94f2493ce920b7b3d532e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Randomized Controlled Trials as Topic
114 rdf:type schema:DefinedTerm
115 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
116 schema:name Medical and Health Sciences
117 rdf:type schema:DefinedTerm
118 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
119 schema:name Oncology and Carcinogenesis
120 rdf:type schema:DefinedTerm
121 sg:journal.1084788 schema:issn 0012-6667
122 1179-1950
123 schema:name Drugs
124 rdf:type schema:Periodical
125 sg:person.01244653776.31 schema:affiliation https://www.grid.ac/institutes/grid.420067.7
126 schema:familyName Scott
127 schema:givenName Lesley J.
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01244653776.31
129 rdf:type schema:Person
130 sg:person.01303054417.19 schema:affiliation https://www.grid.ac/institutes/grid.420067.7
131 schema:familyName Siddiqui
132 schema:givenName M. Asif A.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303054417.19
134 rdf:type schema:Person
135 sg:pub.10.1038/bjc.1997.507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043604506
136 https://doi.org/10.1038/bjc.1997.507
137 rdf:type schema:CreativeWork
138 sg:pub.10.2165/00003495-198300251-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021192528
139 https://doi.org/10.2165/00003495-198300251-00002
140 rdf:type schema:CreativeWork
141 sg:pub.10.2165/00003495-199652050-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037308623
142 https://doi.org/10.2165/00003495-199652050-00002
143 rdf:type schema:CreativeWork
144 https://app.dimensions.ai/details/publication/pub.1074458360 schema:CreativeWork
145 https://doi.org/10.1002/cncr.11817 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010335838
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1016/0277-5379(83)90418-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042962166
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1016/s0959-8049(98)00417-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038757244
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1093/ajhp/56.8.729 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074458360
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1093/annonc/mdg417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047729604
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1093/annonc/mdh047 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026990645
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1111/j.1476-5381.1995.tb13282.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050303878
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1111/j.1476-5381.1995.tb13283.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031465223
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1200/jco.1999.17.9.2971 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549933
162 rdf:type schema:CreativeWork
163 https://www.grid.ac/institutes/grid.420067.7 schema:alternateName Springer (New Zealand)
164 schema:name Adis International Limited, 41 Centorian Drive, Private Bag 65901, 1311, Mairangi Bay, Auckland, New Zealand
165 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...